ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
21.394,93
-0,11%
S&P 500
6.101,24
-0,29%
Dow Jones
44.424,25
-0,32%
Euro vs US Dollar
1,04629
-0,38%
Bitcoin
99.939,79
-2,66%
Pepperstone
Advertisement
Registration Strip Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ

  6. Neurocrine Biosciences Inc (NBIX) Börsenkurse

Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NBIX)

NASDAQ
148,73
1,15
(0,78%)
Geschlossen 27 Januar 10:00PM
Verzögert um 15 Minuten
148,73
0,03
(0,02%)
Nach Börsenschluss: 10:28PM
Verzögert um 15 Minuten

Stärken Sie Ihr Portfolio: Diskussionen in Echtzeit und umsetzbare Handelsideen.

Premium

Wichtige Statistiken und Details

Current Price
148,73
Gebot
146,50
Fragen
151,00
Volumen
946.019
145,9697 Tagesbereich 149,18
110,95 52-Wochen-Bereich 157,9799
Marktkapitalisierung
15,058B
Handelsende
147,58
Handelsbeginn
146,40
Letzte Trade
1
@
146.5
Letzter Handelszeitpunkt
Finanzvolumen
US$ 140.381.178
VWAP
148,3915
Durchschnittliches Volumen (3 Mio.)
970.657
Ausgegebene Aktien
101.246.911
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
60,30
Gewinn pro Aktie (EPS)
2,47
Erlöse
1,89B
Nettogewinn
249,7M

Über Neurocrine Biosciences Inc

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is a... Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome. Mehr anzeigen

Sektor
Biological Pds,ex Diagnstics
Branche
Biological Pds,ex Diagnstics
Website
www.neurocrine.com
Hauptsitz
Wilmington, Delaware, USA
Gegründet
-
Neurocrine Biosciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker NBIX. The last closing price for Neurocrine Biosciences was US$147,58. Over the last year, Neurocrine Biosciences shares have traded in a share price range of US$ 110,95 to US$ 157,9799.

Neurocrine Biosciences currently has 101.246.911 shares in issue. The market capitalisation of Neurocrine Biosciences is US$14,94 billion. Neurocrine Biosciences has a price to earnings ratio (PE ratio) of 60.30.

Option-Flow Neurocrine Biosciences (NBIX)

Vollständigen Option-Flow anzeigen

Gesamtfluss

Bullisch

Nettoprämie

149k

Calls / Puts

100,00%

Käuf. / Verkä.

100,00%

OTM / ITM

0,00%

Sweeps

0,00%

NBIX Neueste Nachrichten

Weitere Nachrichten

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device PR Newswire SAN DIEGO, Jan. 23, 2025 SAN DIEGO, Jan. 23, 2025 /PRNewswire/...

23 Januar 2025
PR Newswire (US)

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism

Neurocrine Biosciences Announces Classic Congenital Adrenal Hyperplasia Supplement Published Today in The Journal of Clinical Endocrinology & Metabolism PR Newswire SAN DIEGO, Jan. 21, 2025...

21 Januar 2025
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

17 Januar 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

15 Januar 2025
Edgar (US Regulatory)

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism

Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism PR Newswire SAN...

08 Januar 2025
PR Newswire (US)

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference PR Newswire SAN DIEGO, Jan. 6, 2025 SAN DIEGO, Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc...

06 Januar 2025
PR Newswire (US)

Form 4 - Statement of changes in beneficial ownership of securities

03 Januar 2025
Edgar (US Regulatory)

Form 144 - Report of proposed sale of securities

31 Dezember 2024
Edgar (US Regulatory)

Form 8-K - Current report

20 Dezember 2024
Edgar (US Regulatory)

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia

Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia PR Newswire SAN DIEGO, Dec. 20, 2024...

20 Dezember 2024
PR Newswire (US)
Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
15.884.11620581029142.85148.73141.57943972145.18960962CS
49.6756.95767861637139.055148.73136.01894625140.51922496CS
1228.2123.4069034185120.52148.73115.34970657131.31029853CS
263.862.66445778974144.87157.9799110.95959095129.32850592CS
527.555.34778297209141.18157.9799110.95888629133.19706423CS
15674.3399.905913978574.4157.979972.28799733114.72920841CS
26046.5645.5711069786102.17157.979971.875819295108.48366964CS

NBIX - Frequently Asked Questions (FAQ)

What is the current Neurocrine Biosciences share price?
The current share price of Neurocrine Biosciences is US$ 148,73
How many Neurocrine Biosciences shares are in issue?
Neurocrine Biosciences has 101.246.911 shares in issue
What is the market cap of Neurocrine Biosciences?
The market capitalisation of Neurocrine Biosciences is USD 14,94B
What is the 1 year trading range for Neurocrine Biosciences share price?
Neurocrine Biosciences has traded in the range of US$ 110,95 to US$ 157,9799 during the past year
What is the PE ratio of Neurocrine Biosciences?
The price to earnings ratio of Neurocrine Biosciences is 60,3
What is the cash to sales ratio of Neurocrine Biosciences?
The cash to sales ratio of Neurocrine Biosciences is 7,98
What is the reporting currency for Neurocrine Biosciences?
Neurocrine Biosciences reports financial results in USD
What is the latest annual turnover for Neurocrine Biosciences?
The latest annual turnover of Neurocrine Biosciences is USD 1,89B
What is the latest annual profit for Neurocrine Biosciences?
The latest annual profit of Neurocrine Biosciences is USD 249,7M
What is the registered address of Neurocrine Biosciences?
The registered address for Neurocrine Biosciences is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Neurocrine Biosciences website address?
The website address for Neurocrine Biosciences is www.neurocrine.com
Which industry sector does Neurocrine Biosciences operate in?
Neurocrine Biosciences operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

Beweger

Alle Anzeigen
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
EVAXEvaxion Biotech AS
US$ 5,99
(64,56%)
55,41M
ELABPMGC Holdings Inc
US$ 3,0901
(56,07%)
76,48M
PCLAPicoCELA Inc
US$ 4,60
(49,35%)
3,75M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
GODNUGolden Star Acquisition Corporation
US$ 3,11
(-75,82%)
17,51k
GODNGolden Star Acquisition Corporation
US$ 2,93
(-65,67%)
902,76k
NXTTNext Technology Holding Inc
US$ 1,37
(-54,93%)
2,56M
SGLYSingularity Future Technology Ltd
US$ 1,625
(-38,45%)
917,77k
WHLRLWheeler Real Estate Investment Trust Inc
US$ 90,11
(-38,07%)
8
ACONAclarion Inc
US$ 0,0557
(28,94%)
811,91M
NVNINVNI Group Ltd
US$ 4,38
(193,96%)
366,98M
RIMEAlgorhythm Holdings Inc
US$ 0,0357
(4,69%)
284,97M
GOEVCanoo Inc
US$ 0,475
(43,94%)
282,22M
NVDANVIDIA Corporation
US$ 142,62
(-3,12%)
232,88M

Foren

Foren anzeigen
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

NASDAQ
NBIX
Neurocrine Biosciences
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2025 ADVFN PLC - Alle Rechte vorbehalten